Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)
GSK Biologicals' Non-Typeable H. influenzae · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study |
| Group B | PLACEBO_COMPARATOR | Subjects in this group will receive placebo in Step 1 of the study |
| Group C | EXPERIMENTAL | Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study |
| Group D | PLACEBO_COMPARATOR | Subjects in this group will receive placebo in Step 2 of the study |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A) | BIOLOGICAL | Administered intramuscularly (IM) in the deltoid region of non-dominant arm |
| GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A) | BIOLOGICAL | 2 doses administered IM in the deltoid region of non-dominant arm |
| Saline placebo | BIOLOGICAL | 2 doses administered IM in the deltoid region of non-dominant arm |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * A male or female between, and including, 18 and 40 years of age at the time of the first vaccination. * Healthy ...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Roivant Sciences Ltd. | ROIV | 2 | PHASE2 | Mosliciguat |
GSK Biologicals' Non-Typeable H. influenzae is an investigational monoclonal antibody being developed by GSK plc for respiratory disorders. It is designed to address non-typeable Haemophilus influenzae, a bacterium associated with respiratory conditions. The candidate is in Phase 1 clinical development and has been studied in a single completed trial.
GSK Biologicals' Non-Typeable H. influenzae is being developed for respiratory disorders. It targets non-typeable Haemophilus influenzae, a pathogen linked to respiratory conditions. The program remains investigational, with one completed Phase 1 trial conducted in healthy adult volunteers in Australia.
GSK Biologicals' Non-Typeable H. influenzae is developed by GSK plc, which trades under the ticker GSK. The candidate is part of GSK's respiratory pipeline and is also identified by the code GSK2838500A. Development is at the Phase 1 stage.
GSK Biologicals' Non-Typeable H. influenzae is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The candidate is investigational and has not been approved for any indication.
GSK Biologicals' Non-Typeable H. influenzae has been evaluated in one completed Phase 1 trial, NCT01657526, titled Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline Biologicals' Non-typeable Haemophilus Influenzae Vaccine. The trial enrolled 48 healthy adult volunteers in Australia and used a randomized, double-blind, placebo-controlled design.
Yes. GSK Biologicals' Non-Typeable H. influenzae is also known as GSK2838500A. Both names refer to the same investigational monoclonal antibody from GSK plc, which is in Phase 1 development for respiratory disorders and has completed one Phase 1 trial.